Edwards Lifesciences Corporation cash flow to debt ratio of 226.14% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Edwards Lifesciences Corporation's free cash flow has increased 360.50% from $289.90M last year to $1.33G, signaling increasing performance

Edwards Lifesciences Corporation's debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Edwards Lifesciences Corporation's debt has decreased relative to shareholder equity from 0.07 last year to 0.07 today, signaling strengthened financials

Edwards Lifesciences Corporation has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Edwards Lifesciences Corporation earns at least as much interest as it pays. Interest obligations are fully covered.

Edwards Lifesciences Corporation's profit margin has decreased (-77.41%) in the last year from 76.75% to 17.34%, signaling decreasing performance

Edwards Lifesciences Corporation's short-term assets of $6.74G exceed its short-term liabilities of $1.81G

Edwards Lifesciences Corporation's return on assets of 8.20% is higher than the 5.00% threshold, indicating efficient asset utilization

Edwards Lifesciences Corporation's return on equity of 10.55%, is lower than 15.00%, indicating bad performance

Edwards Lifesciences Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Edwards Lifesciences Corporation had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Edwards Lifesciences Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

Edwards Lifesciences Corporation has a free cash flow yield of 2.55%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Edwards Lifesciences Corporation's yearly earnings has decreased -74.28% since last year from $4.17G to $1.07G, signaling decreasing performance

Edwards Lifesciences Corporation's yearly revenue has increased 11.55% since last year from $5.44G to $6.07G, signaling increasing performance

ROIC 12.06% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Edwards Lifesciences Corporation's 3-year revenue CAGR of 4.08% is positive, indicating growing revenue over the past 3 years

Edwards Lifesciences Corporation had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Edwards Lifesciences Corporation had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Edwards Lifesciences Corporation is overvalued relative to its fair value price of 44.65 based on Discounted Cash Flow model

Edwards Lifesciences Corporation has an earnings yield of 2.08%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Edwards Lifesciences Corporation is overvalued relative to its fair value price of 21.08 based on EBITDA multiple model

Edwards Lifesciences Corporation has an EV/EBITDA ratio of 35.56x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Edwards Lifesciences Corporation is overvalued relative to its fair value price of 56.67 based on Earnings Fair Value model

Edwards Lifesciences Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Edwards Lifesciences Corporation has a price-to-book ratio of 5.09x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Edwards Lifesciences Corporation has a price-to-sales ratio of 8.29x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue